Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors

Translational Oncology

Volumn 3, Issue 5, 2010, Pages 293-306

  Hillman, Gilda Gali ^a   Singh Gupta, Vinita ^a   Al Bashir, Areen K ^a   Zhang, Hao ^a   Yunker, Christopher K ^a   Patel, Amit D ^a   Sethi, Seema ^a   Abrams, Judith ^a   Mark Haacke, E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETIC ACID; GEMCITABINE; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DYNAMIC CONTRAST ENHANCEMENT; GIANT CELL TUMOR; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY PERFUSION; KIDNEY TUMOR; LOW DRUG DOSE; LUNG METASTASIS; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION; TUMOR GROWTH;

EID: 78449251493     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10136     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Haas GP and Hillman GG (1996). Update on the role of immunotherapy in themanagement of kidney cancer. Cancer Control 3, 536-541.
3. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl JMed 335, 865-875.
4. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. (2006). Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptorand platelet-derived growth factor receptor, in patients with metastatic renalcell carcinoma. J Clin Oncol 24, 16-24.
5. Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, and Haacke EM (2009). Dynamic contrast-enhancedmagnetic resonance imaging of vascular changes induced by sunitinib in papillaryrenal cell carcinoma xenograft tumors. Neoplasia 11, 910-920.
6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003). In vivo antitumor activity of SU11248, a noveltyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderivedgrowth factor receptors: determination of a pharmacokinetic/pharmacodynamicrelationship. Clin Cancer Res 9, 327-337.
7. Abrams TJ, Lee LB, Murray LJ, Pryer NK, and Cherrington JM (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinicalmodels of human small cell lung cancer. Mol Cancer Ther 2, 471-478.
8. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, and Pryer NK (2003). Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeuticagents for the treatment of breast cancer. Mol Cancer Ther 2, 1011-1021.
9. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, et al. (2003). SU11248 inhibitstumor growth and CSF-1R-dependent osteolysis in an experimental breast cancerbone metastasis model. Clin Exp Metastasis 20, 757-766.
10. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al. (2003). SU11248 is a novel FLT3 tyrosinekinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605.
11. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O'Farrell AM, Gilliland DG, Le Beau MM, et al. (2003). A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101, 3188-3197.
12. Xu L, Tong R, Cochran DM, and Jain RK (2005). Blocking platelet-derivedgrowth factor-D/platelet-derived growth factor receptor beta signaling inhibitshuman renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65, 5711-5719.
13. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, and Teh BT (2010). Sunitinib acts primarily on tumor endothelium ratherthan tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70,1053-1062.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferonα in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. (2009). Overall survivaland updated results for sunitinib compared with interferon α in patients withmetastatic renal cell carcinoma. J Clin Oncol 27, 3584-3590.
16. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, and Bjarnason G (2007). Sunitinib therapy for metastatic renal cell carcinoma: recommendationsfor management of side effects. Can Urol Assoc J 1, S41-S54.
17. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. (2007). Cardiotoxicity associatedwith tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
18. Telli ML, Witteles RM, Fisher GA, and Srinivas S (2008). Cardiotoxicity associatedwith the cancer therapeutic agent sunitinib malate. Ann Oncol 19, 1613-1618.
19. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, and Schmidinger H (2008). Cardiac toxicity of sunitinib and sorafenib inpatients with metastatic renal cell carcinoma. J Clin Oncol 26, 5204-5212.
20. Jain RK (2005). Normalization of tumor vasculature: an emerging concept inantiangiogenic therapy. Science 307, 58-62.
21. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: anew paradigm for combination therapy. Nat Med 7, 987-989.
22. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007). Integrationof quantitative DCE-MRI and ADC mapping to monitor treatment responsein human breast cancer: initial results. Magn Reson Imaging 25, 1-13.
23. Jackson A, O'Connor JP, Parker GJ, and Jayson GC (2007). Imaging tumorvascular heterogeneity and angiogenesis using dynamic contrast-enhanced magneticresonance imaging. Clin Cancer Res 13, 3449-3459.
24. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, and Stadler WM (2008). Dynamic contrast-enhancedmagnetic resonance imaging pharmacodynamic biomarker study of sorafenib inmetastatic renal carcinoma. J Clin Oncol 26, 4572-4578.
25. Hylton N (2006). Dynamic contrast-enhanced magnetic resonance imaging asan imaging biomarker. J Clin Oncol 24, 3293-3298.
26. Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR (2003). Use ofdynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89, 1889-1895.
27. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, et al. (2005). Early antiangiogenic activity of SU11248evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in anexperimental model of colon carcinoma. Clin Cancer Res 11, 5827-5832.
28. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, and Stadler WM (2002). Ahigh rate of venous thromboembolism in amulti-institutional phase II trial of weeklyintravenous gemcitabine with continuous infusion fluorouracil and daily thalidomidein patients with metastatic renal cell carcinoma. Cancer 95, 1629-1636.
29. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, and Jonasch E (2008). A phase II trial of gemcitabine pluscapecitabine for metastatic renal cell cancer previously treated with immunotherapyand targeted agents. J Urol 180, 867-872.
30. Amato RJ and Khan M (2008). A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastaticrenal cell carcinoma. Cancer Chemother Pharmacol 61, 1069-1073.
31. Perez-Zincer F, Olencki T, Budd GT, Peereboom D, Elson P, and Bukowski RM (2002). A phase I trial of weekly gemcitabine and subcutaneous interferon α inpatients with refractory renal cell carcinoma. Invest New Drugs 20, 305-310.
32. Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, and Sarkar FH (2007). Progression of renal cell carcinoma is inhibited by genistein and radiationin an orthotopic model. BMC Cancer 7, 4.
33. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, and Sarkar FH (2004). Genistein potentiates inhibitionof tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3, 1271-1279.
34. Haacke EM, Filleti CL, Gattu R, Ciulla C, Al-Bashir A, Suryanarayanan K, Li M, Latif Z, DelProposto Z, Sehgal V, et al. (2007). New algorithm for quantifyingvascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med 58, 463-472.
35. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, and Hillman GG (2007). Down-regulation of apurinic/apyrimidinicendonuclease 1/redox factor-1 expression by soy isoflavones enhances prostatecancer radiotherapy in vitro and in vivo. Cancer Res 67, 2141-2149.
36. Holm S (2009). A simple sequentially rejective multiple test procedure. Scand JStatist 6, 65-70.
37. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacyagainst experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
38. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24.
39. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, and van Oosterom AT (2003). Effect of antivascular endothelialgrowth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88,1979-1986.
40. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, et al. (2004). Antiangiogenic versus cytotoxictherapeutic approaches to human pancreas cancer: an experimental studywith a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitorand gemcitabine. Eur J Pharmacol 498, 9-18.
41. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, et al. (2008). Early changes in functionaldynamic magnetic resonance imaging predict for pathologic response to neoadjuvantchemotherapy in primary breast cancer. Clin Cancer Res 14, 6580-6589.
42. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, et al. (2009). The parametricresponse map is an imaging biomarker for early cancer treatment outcome. Nat Med 15, 572-576.
43. Craciunescu OI, Blackwell KL, Jones EL, Macfall JR, Yu D, Vujaskovic Z, Wong TZ, Liotcheva V, Rosen EL, Prosnitz LR, et al. (2009). DCE-MRI parametershave potential to predict response of locally advanced breast cancer patientsto neoadjuvant chemotherapy and hyperthermia: a pilot study. Int J Hyperthermia 25, 405-415.
44. Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, Galan M, Ribas IG, Germa JR, Capella G, and Vinals F (2008). Antiangiogenic effect of gemcitabinefollowing metronomic administration in a pancreas cancer model. Mol Cancer Ther 7, 638-647.